Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. (“Nxera”; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders.
SAN ANTONIO, Aug. 5, 2025 /PRNewswire/ -- A groundbreaking multicenter clinical study published on July 30 in JAMA Surgery confirms the powerful diagnostic performance...
"Market Analysis Highlights Growth Potential, Emerging Technologies, ESG Trends, and Strategic Insights in the Cell Line and Membrane Sector"
BOSTON, Aug. 5, 2025 /PRNewswire/ --...
PALO ALTO, Calif., Aug. 5, 2025 /PRNewswire/ -- As sanction regimes become more complex and scrutiny intensifies, institutions need more than a list; they...
The cell culture market is anticipated to expand at a rapid pace owing to growing innovations in biotechnologies, and biopharmaceuticals on the back of...
The newly FDA-cleared uMR® Ultra and the uOmniscan™ are the first major announcements leading into the AHRA Annual Meeting in Las Vegas.
HOUSTON, Aug. 3, 2025...
LUXEMBOURG , Aug. 02, 2025 (GLOBE NEWSWIRE) -- Bitcoin Swift, a blockchain protocol combining Proof-of-Work (PoW), Proof-of-Stake (PoS), and an AI-powered Proof-of-Yield (PoY) mechanism, has officially entered Stage 3 of its presale. The platform is offering tokens at $3 during this limited 64-day window, with a scheduled increase to $4 in the next stage and a confirmed launch price of $15.
Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.1 Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.
SOUTHAMPTON, England, July 30, 2025 /PRNewswire/ -- MODERNISED (NIHR207538), a multi-site UK clinical study has passed a key milestone: over 450 participants have joined the...
SOUTHAMPTON, England, July 30, 2025 /PRNewswire/ -- MODERNISED (NIHR207538), a multi-site UK clinical study has passed a key milestone: over 450 participants have joined the...
ARLINGTON, Va., July 29, 2025 /PRNewswire/ -- A new report from Kalorama Information reveals that the global point-of-care (POC) diagnostics market surged past $36 billion...